SGH
Sivik Global Healthcare Portfolio holdings
AUM
$224M
This Quarter Return
+6.87%
1 Year Return
+5.3%
3 Year Return
+45.33%
5 Year Return
+103.79%
10 Year Return
+430.94%
AUM
$269M
AUM Growth
+$269M
(-8.1%)
Cap. Flow
-$28.2M
Cap. Flow
% of AUM
-10.48%
Top 10 Holdings %
Top 10 Hldgs %
26.22%
Holding
94
New
17
Increased
21
Reduced
26
Closed
21
Top Buys
| 1 |
HCA Healthcare
HCA
|
$7.47M |
| 2 |
Universal Health Services
UHS
|
$6.8M |
| 3 |
Viatris
VTRS
|
$5.08M |
| 4 |
Bristol-Myers Squibb
BMY
|
$4.6M |
| 5 |
Johnson & Johnson
JNJ
|
$4.19M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$8.51M |
| 2 |
Agilent Technologies
A
|
$6.74M |
| 3 |
Gilead Sciences
GILD
|
$6.48M |
| 4 |
AET
Aetna Inc
AET
|
$6.31M |
| 5 |
Revvity
RVTY
|
$6.21M |
Sector Composition
| 1 | Healthcare | 92.84% |
| 2 | Financials | 1.34% |
| 3 | Energy | 1.14% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Stryker
SYK
$150B
| $4.65M | 1.72% |
30,000
-20,000
| -40% | -$3.1M |
|
|
27
Bristol-Myers Squibb
BMY
$96B
| $4.6M | 1.71% |
+75,000
| New | +$4.6M |
|
28
Zoetis
ZTS
$69.3B
| $4.32M | 1.6% |
60,000
-5,000
| -8% | -$360K |
|
|
29
Johnson & Johnson
JNJ
$427B
| $4.19M | 1.56% |
+30,000
| New | +$4.19M |
|
|
GWPH
30
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $3.96M | 1.47% |
30,000
+5,000
| +20% | +$660K |
|
31
Becton Dickinson
BDX
$55.3B
| $3.65M | 1.35% |
17,038
-15,462
| -48% | -$3.31M |
|
|
AET
32
DELISTED
Aetna Inc
AET
| $3.61M | 1.34% |
20,000
-35,000
| -64% | -$6.31M |
|
|
BLUE
33
DELISTED
bluebird bio
BLUE
| $3.56M | 1.32% |
20,000
+2,500
| +14% | +$445K |
|
34
Align Technology
ALGN
$10.3B
| $3.56M | 1.32% |
16,000
+2,600
| +19% | +$578K |
|
35
Puma Biotechnology
PBYI
$254M
| $3.46M | 1.28% |
35,000
+15,000
| +75% | +$1.48M |
|
36
Insulet
PODD
$23.9B
| $3.45M | 1.28% |
+50,000
| New | +$3.45M |
|
37
Smith & Nephew
SNN
$16.3B
| $3.33M | 1.23% |
95,000
-25,000
| -21% | -$875K |
|
|
SAGE
38
DELISTED
Sage Therapeutics
SAGE
| $3.29M | 1.22% |
+20,000
| New | +$3.29M |
|
39
Illumina
ILMN
$15.8B
| $3.28M | 1.22% |
15,000
| – | – |
|
40
Labcorp
LH
$23.1B
| $3.19M | 1.18% |
20,000
+6,100
| +44% | +$973K |
|
|
CTLT
41
DELISTED
CATALENT, INC.
CTLT
| $3.08M | 1.14% |
75,000
+33,600
| +81% | +$1.38M |
|
|
LHCG
42
DELISTED
LHC Group LLC
LHCG
| $3.06M | 1.14% |
50,000
-910
| -2% | -$55.7K |
|
43
Tenet Healthcare
THC
$16.3B
| $3.03M | 1.13% |
+200,000
| New | +$3.03M |
|
44
Bio-Rad Laboratories Class A
BIO
$8.06B
| $2.98M | 1.11% |
12,500
+2,500
| +25% | +$597K |
|
|
EVHC
45
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $2.94M | 1.09% |
+85,000
| New | +$2.94M |
|
46
Dr. Reddy's Laboratories
RDY
$11.8B
| $2.82M | 1.05% |
75,000
+25,000
| +50% | +$939K |
|
|
LPNT
47
DELISTED
LifePoint Health, Inc.
LPNT
| $2.74M | 1.02% |
+55,000
| New | +$2.74M |
|
48
Neurocrine Biosciences
NBIX
$13.8B
| $2.72M | 1.01% |
35,000
+5,000
| +17% | +$388K |
|
49
Novo Nordisk
NVO
$251B
| $2.68M | 1% |
+50,000
| New | +$2.68M |
|
|
ESRX
50
DELISTED
Express Scripts Holding Company
ESRX
| $2.61M | 0.97% |
35,000
+5,000
| +17% | +$373K |
|